NCT04568200View on ClinicalTrials.gov

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

January 1, 2024

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Durvalumab

Durvalumab 1500mg i.v. day 1-22-43-64

DRUG

Carboplatin

Chemotherapy

DRUG

Paclitaxel

Chemotherapy

RADIATION

Radiotherapy 23 x 1.8 Gy

Radiotherapy 23 x 1.8 Gy

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04568200 - Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter